🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

The Affiliated Hospital of Hangzhou Normal University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with The Affiliated Hospital of Hangzhou Normal University as lead sponsor. Synced 26 Sep 2026
8Current trials
3Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 8 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Observational. The most-studied condition is MAFLD.

ClinicalTrials.gov trials by status

  • Recruiting338%
  • Not yet open450%
  • By invitation113%

Trials by phase

  • Observational563%
  • Not applicable338%
01

Clinical trials sponsored by The Affiliated Hospital of Hangzhou Normal University

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD
NCT07233486 · ClinicalTrials.gov ↗ · MAFLD
Not applicable Recruiting 2024-08 China
Acute Effects of Meteorological Factors and Air Pollution on Cardiovascular Health
NCT06663267 · ClinicalTrials.gov ↗ · Cardiovascular System, Health
Observational Recruiting 2024-11 China
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
NCT07241195 · ClinicalTrials.gov ↗ · NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis
Observational Recruiting 2026-03 China
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
NCT07706010 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Observational Not yet open 2026-07 China
Chinese Cardiologists' Knowledge/Practices on Flu Vaccine for Chronic Coronary Syndrome
NCT06991088 · ClinicalTrials.gov ↗ · Chinese Cardiologists
Observational Not yet open 2025-06 China
Prospective Cohort Study of Aging in Patients With Acute Myocardial Infarction
NCT07705997 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI)
Observational Not yet open 2026-08 China
Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease
NCT07399600 · ClinicalTrials.gov ↗ · Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome
Not applicable Not yet open 2026-02 China
Study on Treatment Mechanisms and Efficacy Prediction of Individualized Transcranial Magnetic Stimulation in Adults With Irritable Bowel Syndrome Using Multimodal MRI and High-Throughput Sequencing
NCT07345377 · ClinicalTrials.gov ↗ · Irritable Bowel Syndrome (IBS), Pain, Depressive Disorder, Major, Moderate
Not applicable By invitation 2022-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in The Affiliated Hospital of Hangzhou Normal University trials

16 conditions
MAFLD1Type 2 Diabetes (T2DM)1Metabolic Dysfunction-Associated Steatotic Liver Disease1Chinese Cardiologists1Cardiovascular System1Health1Acute Myocardial Infarction (AMI)1Irritable Bowel Syndrome (IBS)1Pain1Depressive Disorder, Major, Moderate1Liver Diseases, Alcoholic1Fatty Liver1Metabolic Syndrome1NAFLD and NASH1NAFLD( Non-alcoholic Fatty Liver Disease )1NAFLD Cirrhosis1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China83

A trial with sites in more than one country appears in each of those registers.

04

Questions about The Affiliated Hospital of Hangzhou Normal University trials

How many clinical trials does The Affiliated Hospital of Hangzhou Normal University sponsor?

The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The Affiliated Hospital of Hangzhou Normal University trials recruiting?

Yes. 3 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.